Centogene N.V. Stock News

Shares of Centogene NV CNTG, +8.31% gained 7% premarket on Friday after the company announced data confirming the utility of its proprietary biomarker lyso-Gb1 in indicating the severity of Gaucher di

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera

Shares of Centogene NV CNTG, -2.20%, which specializes in genetic diagnostics for rare diseases, jumped 50% in premarket trading Tuesday after the company announced a joint venture with Lifera, a biop

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 05, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerati

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegener

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 08, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenera

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerat

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegene

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegener

Centogene N.V. (CNTG) CEO Kim Stratton on Q4 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,

Hoboken, NJ, Rostock/Berlin, Germany, Feb 22, 2022 - (ACN Newswire) - Based on Whole Genome Sequencing (WGS), Arcensus GmbH makes it possible to detect rare as well as frequent disorders such as cancer or heart diseases at the earliest stage in order to start preventive and personalized treatment. One year after Arcensus was founded, fresh capital is now being raised for further expansion. As part of the current investment-series the Mittelstandische Beteiligungsgesellschaft Mecklenburg-Vorpommern (MBMV) are investing a single-digit million to further expand into the US and GCC regions. For MBMV, it is a very special investment, as Managing Director Dr. Thomas Drews reveals: "With Arcensus, we are investing in a very experienced and well-known team and in a technology which, in precisely this combination, has the potential to make a major contribution to the prevention of diseases and the cure of rare diseases". He continues: "In addition, we are proud that a local company from Rostock is able to play as a figurehead at the top of the international biotech scene." Indeed, the team around Prof.

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc. (NASDAQ: AXSM ) disclosed in a filing that it reached a settlement with Baudax Bio, Inc. (NASDAQ: BXRX ) with regard to a lawsuit alleging that Axsome''s AXS-07 infringed a couple of patents owned by Baudax. Under the settlement agreement, Baudax is to voluntarily dismiss the lawsuit and Axsome will make a one-time payment of $312,500 to Baudax. Axsome has not incurred any obligation to pay any royalty or other contingent consideration nor has it agreed to any other restriction on its manufacture or distribution of AXS-07. Axsome shares were down 3.01% to $29.60 in premarket trading. Editas Announces Termination Of Chief Medical Office With Immediate Effect Editas Medicine, Inc. (NASDAQ: EDIT ) said in a filing with the SEC that Lisa Michaels'' employment with Editas as its chief medical officer was terminated, effective immediately.